Literature DB >> 23443489

Secondary cytoreduction versus chemotherapy alone in the treatment of patients with recurrent ovarian cancer: is a randomized trial worthwhile?

Paolo Sammartino, Daniele Biacchi, Marialuisa Framarino.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23443489     DOI： 10.1007/s11912-013-0302-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  4 in total

Review 1.  Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer.

Authors:  Jonathan A Ledermann; Fharat A Raja
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

2.  Surgery for relapsed ovarian cancer: when should it be offered?

Authors:  Philipp Harter; Florian Heitz; Andreas du Bois
Journal:  Curr Oncol Rep       Date:  2012-12       Impact factor: 5.075

Review 3.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

4.  Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.

Authors:  R Y Zang; P Harter; D S Chi; J Sehouli; R Jiang; C G Tropé; A Ayhan; G Cormio; Y Xing; K M Wollschlaeger; E I Braicu; C A Rabbitt; H Oksefjell; W J Tian; C Fotopoulou; J Pfisterer; A du Bois; J S Berek
Journal:  Br J Cancer       Date:  2011-08-30       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.